Elanco Animal Health Inc Q4 2019 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ekaterina V. Knyazkova - JP Morgan Chase & Co, Research Division - Analyst : This is actually Ekaterina on for Chris. So the first question is, can you provide a little bit more color on the quarterly gaining of gross margins in 2020? Is the gross margin progression we saw in 2019 a decent way to think about 2020? Or should we think about more consistent margins

Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst : I apologize. My call dropped a couple of times, so if I missed this. So I noticed there were some changes in your distribution strategy with small distributors. Is there any contemplation of maybe disruption of distributors in the guidance? And is this kind of a signal of maybe future strategy around distribution? And then my second question was on Entyce. I'm not sure if you can give maybe kind of a peak sales, but it is a very good product, and it finally has the backing of a very large sales force. So is there any thoughts you could see go from term to total market, maybe not quantitative but qualitative? And then is there an additional maybe leg-ups with Entyce for cat? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. FEBRUARY 19, 2020 / 1:00PM, ELAN.N - Q4 2019 Elanco Animal Health Inc Earnings Call